01COMPLETE
Define the target stool
Formed and consistent enough to support normal bowel mechanics, without aiming for excessive hardness.
We did not begin with a trendy ingredient and build a story around it. We began with an overlooked canine-health problem, defined the stool outcome we wanted, and built a focused formula around the different jobs fiber must perform.
A common, frustrating and under-researched pattern.
Structure without simply making stool harder.
Different fiber behaviors, one focused purpose.
Test the chew—not only its individual ingredients.
Most products begin with familiar ingredients. Kynalia began with a narrower question: why do some dogs keep returning to the same cycle of scooting, odor and manual expression?
dogs under primary veterinary care had a recorded anal-sac disorder within one year in a large study.
Different fibers bind water differently, add different amounts of bulk, ferment at different rates, and affect stool in different ways. That meant a credible formula could not be designed by choosing the most familiar ingredient or copying a competitor’s label.
We first defined the target: a stool that is formed enough to create natural pressure, but still comfortable to pass. Then we evaluated each candidate according to the job it would perform inside that system.
Every functional ingredient needed a defined role.
Every functional amount would be disclosed.
Ingredient evidence would not be presented as a product trial.
The process moved from physiology to ingredient behavior, then to a complementary architecture, transparent dose model and finished-product testing plan.
Formed and consistent enough to support normal bowel mechanics, without aiming for excessive hardness.
Compare water binding, bulk, fermentability, stool moisture, tolerance and relevance of available canine research.
Reject the idea that one fiber must do everything. Combine distinct functions without filling the label with extras.
Show each functional amount per chew and scale daily intake across three practical dog-size ranges.
Move from rationale to direct evidence through batch verification, tolerance work and controlled outcome research.
This screen prevented Kynalia from becoming a generic “everything supplement.” An ingredient stayed only when it contributed to the target formula architecture.
Does it absorb, retain or redistribute water in a way that supports the intended stool profile?
Does it contribute physical bulk and shape without pushing the stool toward excessive hardness?
Is it poorly, moderately or highly fermentable—and how could that affect tolerance and the microbiome?
Is the intended daily amount practical in a soft chew and appropriate for gradual daily use?
Was the research conducted in dogs, at a comparable dose, and on an outcome relevant to our intended claim?
The ingredients have research-informed rationales. That does not mean the finished Kynalia chew is clinically proven; direct finished-product testing remains a separate evidence layer.
Gel-forming fiber selected for water management and stool consistency.
Canine stool evidence · different dose and populationPoorly fermentable insoluble fiber selected for bulk and physical structure.
Canine digestion evidence · no anal-gland endpointModerately fermentable mixed fiber selected to complement cellulose.
Canine stool research · effect differs from celluloseComplementary plant-fiber profile used to broaden the architecture.
Limited comparable canine outcome evidenceTargeted prebiotic substrate included without adding a decorative probiotic blend.
Canine microbiome evidence · published dose is higherReal credibility comes from showing which level of evidence supports each statement—and what remains to be demonstrated on the finished product.
Canine anatomy, normal bowel mechanics, epidemiology and recognized anal-sac risk factors.
Published canine studies used to understand fiber behavior, stool outcomes and prebiotic rationale.
Identity, microbiology, contaminants, uniformity, physical specifications and shelf-life work.
Tolerance, adherence and stool-score measurement on dogs receiving the actual Kynalia chew.
A blinded, placebo-controlled study with prespecified finished-product outcomes.
“Premium” should describe a documented process—not a jar, a color palette or a collection of familiar ingredients.
Approved specifications, traceable source documentation and review of certificates before materials enter production.
Confirm that incoming materials match the ingredient and specification selected during development.
Release specifications for relevant pathogens, total microbial count, yeast and mold.
Compare independent results against documented limits rather than using the misleading phrase “zero contaminants.”
Evaluate chew weight, blend distribution, count, appearance and physical consistency across the batch.
Confirm that safety and quality specifications remain acceptable through the intended shelf life.
The most credible path moves from product quality and tolerance to direct outcome testing—and reports results whether they are positive, negative or inconclusive.
Verify that the physical product matches the formula specification and remains safe and consistent through its intended shelf life.
A prospective feasibility study using the finished chew to assess tolerance, adherence and how reliably stool outcomes can be measured.
A randomized, blinded, placebo-controlled study designed around outcomes the product actually claims to influence.
Change in a predefined, consistently applied fecal or stool-form score.
Veterinarian-assessed anal-sac fullness or frequency of manual expression.
Scooting, licking, odor and owner-observed comfort recorded in standardized diaries.
Randomized, blinded and placebo-controlled, with sample size determined through power analysis.
Trust is built by disclosing uncertainty, limitations and status—not by making every research citation sound like proof of the finished product.
Every functional amount is shown per chew.
An ingredient study will not be presented as a Kynalia product trial.
Numerical outcomes will appear only when supported by the corresponding study.
Planned, in-progress, completed and published work will be labeled differently.
Negative and inconclusive findings belong in the evidence record too.
Technical language and citations must help owners evaluate the formula—not merely impress them.
Kynalia exists to take narrow canine-health problems seriously: define the target, disclose the dose, show the evidence boundary, and keep testing the finished product after launch.
Explore Anal Gland + Stool Support →No finished-product clinical trial should be claimed until that study is completed. The current architecture is research-informed: it uses published physiology and ingredient evidence, while direct finished-formula validation remains a separate planned step.
It means published research exists on individual ingredients or related fiber types. Study populations, doses and endpoints may differ from Kynalia, so this language does not mean the finished chew produced the same results.
Use that statement only after the release program and independent laboratory documentation are operational for every applicable batch. Until then, the page should describe it as a required pre-release quality standard.
Fiber sources differ in water binding, bulk and fermentability. The blend was designed to combine different roles rather than expecting one familiar ingredient to provide every desired property.
The proposed research charter commits to reporting negative and inconclusive findings alongside positive results. That promise should be formalized in study protocols before clinical work begins.
Primary veterinary research and official quality guidance used to shape the formula rationale and testing roadmap.
Veterinary Record · VetCompass epidemiology and research gaps
BMC Veterinary Research · canine psyllium study
Journal of Animal Science · distinct stool and digestion effects
Bioscience of Microbiota, Food and Health · microbiome study
Federal Trade Commission · substantiation and implied claims
Independent audit, quality procedures and adverse-event systems